bloed cell cancer hematological lymphoid and myeloid malignancies
Conditions
Interventions
Suitable patients will be vaccinated with ex vivo cultured donor DCs that are
a) silenced for PD-L molecules by means of a siRNA transfection methodology and
b) loaded with peptides of the UTA2-1 an
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patients with Multiple Myeloma (MM) or Chronic Lymphocytic Leukemia (CLL) or non hodgkin lymphoma (any grade) or acute myeloid leukemia (AML) 2. Recipient and donor have a mismatch in UTA2-1 mHag in the Graft versus Tumor (GvT) direction (recipient mHag positive, donor mHag negative). 4. Recipient and donor are positive for HLA-A*0201 5. Age 18-75 years 6. Absence of acute GvHD > grade 1 or extensive chronic GvHD 7. No treatment with immunosuppressive drugs such as prednisone, cyclosporine A and MMF at least 4 weeks prior to planned vaccination date. 8. WHO performance 0-2 9. Absence of severe cardiac hepatic, renal, or metabolic disease 10. Written informed consent
Exclusion criteria
Exclusion criteria: 1. WHO performance 3-4 2. Presence of severe cardiac hepatic, renal, metabolic disease 3. Rapidly progressive disease, 4. Life expectancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -To evaluate the toxicity and feasibility of a preemptive minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC vaccination - To evaluate the effect of minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC vaccination on the immune status of the recipient in correlation with toxicity and response, including the investigation of the induction of UTA2-1 specific T cell responses after vaccination. | — |
Secondary
| Measure | Time frame |
|---|---|
| -to evaluate the efficacy of the minor H ag UTA2-1 peptide-loaded, PD-L silenced donor DC vaccination to induce a GvT effect. | — |
Countries
Netherlands
Outcome results
None listed